Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF ...

In some parts of the world, record numbers of people are being diagnosed with attention deficit hyperactivity disorder (ADHD) ...

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE OLE data analysis supports the ability to ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...

Protagonist Therapeutics, Inc. ("Protagonist") and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with ...

The analysis of an exploratory composite endpoint revealed that early treatment with AP-101 prolonged survival and delayed ventilatory support in comparison to study participants ...

Genmab A/S today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...

US FDA approves Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma: Princeton, New Jersey Saturday, December 6, 2025, 09:00 Hrs [IST] ...